Back to search

Japan· JP-6162001M1041

サイクロセリン

A cycloserine product containing サイクロセリン, registered in Japan by Meiji Seika ファルマ, on the national reimbursement list. The same ATC class is registered in 6 of our 19 countries.

On Japan’s NHI price listATC J04AB01

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedサイクロセリンATCJ04AB01REGISTER NO.JP-6162001M1041PACKS LISTED0CHECKEDSeptember 25, 2026

Where it is registered

Cycloserine is registered in 6 of 19 countries.

Countries holding a registration under ATC J04AB01 (cycloserine), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 4 of them publish a price we can compare per daily dose

Cycloserine · ATC J04AB01

6 / 19 countries

  • Czechiaprice
  • Finlandprice
  • Japan
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
サイクロセリン
Manufacturer
Meiji Seika ファルマ
Country
Japan (JP)
ATC code
J04AB01
ATC class
Cycloserine
Defined daily dose
0.75 g, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

17 interactions on record for cycloserine.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cycloserine · interactions on record

17 records

  • 8 severe
  • 9 moderate

Most severe, free to view

  • EthanolB05XX04severe
  • BupropionN06AX12severe
  • BupropionN07BA02severe
  • EthanolV03AB16severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cycloserine in 4 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cycloserine products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • United Kingdom (Northern Ireland) · Cycloserine Neon Healthcare
  • Romania · Cicloserină Antibiotice

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5b99bac8-ac33-4c0a-a435-d82e39a264c7
GET /v1/drugs/5b99bac8-ac33-4c0a-a435-d82e39a264c7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "250mg1カプセル",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "6162001M1041",
  "category": "内用薬",
  "price_yen": 340.1,
  "generic_name": "サイクロセリン",
  "product_name_jp": null,
  "therapeutic_class": "6162",
  "transitional_expiry": null
}

See everything about cycloserine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.